Navidea Biopharmaceuticals Presents New Data on Precision Diagnostic Platform at Harvard Medical School Conference

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, presented collaborative data at the Cancer Advance Conference at Harvard Medical School from proof-of-principle imaging studies using tilmanocept-Cy3, a fluorescent-labeled agent from the Company’s Manocept™ platform, utilizing technical principle underlying Navidea’s FDA-approved lymphatic mapping product, Lymphoseek® (technetium 99m tilmanocept) Injection.

Help employers find you! Check out all the jobs and post your resume.

Back to news